The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

By S. Ponader, Shih-Shih Chen, J. Buggy, K. Balakrishnan, V. Gandhi, W. Wierda, M. Keating, S. O'brien, N. Chiorazzi, J. Burger. Blood, 2012

650 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/61d3f5c0b26beea64036ed1e56dd1f278a1d73eb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Simar Pal Singh
2. Floris Dammeijer
3. R. Hendriks

Citations in the corpus

• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia (2015, neutral): “Platelet count ≤100,000/mm3 35 (26) 28 (21)”
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, neutral): “,60 mL/min, n (%) 9 (29) 20 (20) 29 (22)”
• Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “reduce secretion of BCR-dependent chemokines CCL3 and CCL4 [142].”
• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia (2014, neutral): “Neutropenia 42 (22) 32 (16) 28 (15) 26 (14)”